Ethacrynic acid: two years' experience with a new diuretic.
D001581:Benzothiadiazines / Q000627:therapeutic use; D001769:Blood; D004487:Edema / Q000188:drug therapy*; D004976:Ethacrynic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000188:drug therapy; D009941:Organomercury Compounds / Q000627:therapeutic use; D011188:Potassium; D011504:Protein-Losing Enteropathies / Q000188:drug therapy; D012964:Sodium; D013148:Spironolactone / Q000627:therapeutic use; D014556:Urine
D001581:Benzothiadiazines; D009941:Organomercury Compounds; D013148:Spironolactone; D012964:Sodium; D004976:Ethacrynic Acid; D011188:Potassium
Circulation. 1951 Jul;4(1):54-60
14848954
Br Med J. 1963 Jun 8;1(5344):1521-4
13934763
Br Med J. 1963 Nov 9;2(5366):1169-71
14060916
J Clin Invest. 1964 Feb;43:201-16
14162529
J Clin Invest. 1964 Jul;43:1495-506
14192531
Lancet. 1964 May 2;1(7340):947-52
14121351
Ann Intern Med. 1965 Jan;62:15-29
14258343
Clin Pharmacol Ther. 1965 Jul-Aug;6:474-85
14314971
Klin Wochenschr. 1964 Oct 1;42:958-65
14323809
JAMA. 1963 Sep 14;185:854-63
14046649
Circulation. 1965 Jan;31:5-18
14247531